8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.
Topic archive
substance use disorder
3 stories
7/24/2026
Ibogaine aids ketamine abstinence, case report suggests
Case report highlights ibogaine's potential in treating severe ketamine use disorder.
7/16/2026
Ibogaine: A psychoactive compound with potential
Ibogaine's role in treating substance use disorders remains controversial.